156 related articles for article (PubMed ID: 9493588)
41. Serine protease inhibitor nafamostat given before reperfusion reduces inflammatory myocardial injury by complement and neutrophil inhibition.
Schwertz H; Carter JM; Russ M; Schubert S; Schlitt A; Buerke U; Schmidt M; Hillen H; Werdan K; Buerke M
J Cardiovasc Pharmacol; 2008 Aug; 52(2):151-60. PubMed ID: 18670364
[TBL] [Abstract][Full Text] [Related]
42. GPV is a marker of in vivo platelet activation--study in a rat thrombosis model.
Ravanat C; Freund M; Mangin P; Azorsa DO; Schwartz C; Moog S; Schuhler S; Dambach J; Cazenave JP; Lanza F
Thromb Haemost; 2000 Feb; 83(2):327-33. PubMed ID: 10739394
[TBL] [Abstract][Full Text] [Related]
43. Blood platelet activation and membrane glycoprotein changes during extracorporeal life support (ECLS). In vitro studies.
Mellgren K; Friberg LG; Hedner T; Mellgren G; Wadenvik H
Int J Artif Organs; 1995 Jun; 18(6):315-21. PubMed ID: 8593966
[TBL] [Abstract][Full Text] [Related]
44. Effect of glycoprotein IIb/IIIa inhibitors on CD62p expression, platelet aggregates, and microparticles in vitro.
Matzdorff AC; Kühnel G; Kemkes-Matthes B; Pralle H; Voss R; Fareed J
J Lab Clin Med; 2000 Mar; 135(3):247-55. PubMed ID: 10711863
[TBL] [Abstract][Full Text] [Related]
45. Platelet activation during angiotensin II infusion in healthy volunteers.
Larsson PT; Schwieler JH; Wallén NH
Blood Coagul Fibrinolysis; 2000 Jan; 11(1):61-9. PubMed ID: 10691100
[TBL] [Abstract][Full Text] [Related]
46. Thrombin and human plasma kallikrein inhibition during simulated extracorporeal circulation block platelet and neutrophil activation.
Wachtfogel YT; Kettner C; Hack CE; Nuijens JH; Reilly TM; Knabb RM; Kucich U; Niewiarowski S; Edmunds LH; Colman RW
Thromb Haemost; 1998 Oct; 80(4):686-91. PubMed ID: 9798991
[TBL] [Abstract][Full Text] [Related]
47. Activation of coagulation and platelets by candidate membranes of implantable devices in a whole blood model without soluble anticoagulant.
Sokolov A; Hellerud BC; Tønnessen TI; Johannessen EA; Mollnes TE
J Biomed Mater Res A; 2013 Feb; 101(2):575-81. PubMed ID: 22949225
[TBL] [Abstract][Full Text] [Related]
48. Mechanisms of synthetic serine protease inhibitor (FUT-175)-mediated cell death.
Uwagawa T; Li Z; Chang Z; Xia Q; Peng B; Sclabas GM; Ishiyama S; Hung MC; Evans DB; Abbruzzese JL; Chiao PJ
Cancer; 2007 May; 109(10):2142-53. PubMed ID: 17410536
[TBL] [Abstract][Full Text] [Related]
49. Prostacyclin in lieu of anticoagulation with heparin for extracorporeal circulation.
Addonizio VP; Fisher CA; Bowen JC; Palatianos GC; Colman RW; Edmunds LH
Trans Am Soc Artif Intern Organs; 1981; 27():304-7. PubMed ID: 7036500
[TBL] [Abstract][Full Text] [Related]
50. Comparison of minimally invasive closed circuit extracorporeal circulation with conventional cardiopulmonary bypass and with off-pump technique in CABG patients: selected parameters of coagulation and inflammatory system.
Wippermann J; Albes JM; Hartrumpf M; Kaluza M; Vollandt R; Bruhin R; Wahlers T
Eur J Cardiothorac Surg; 2005 Jul; 28(1):127-32. PubMed ID: 15939621
[TBL] [Abstract][Full Text] [Related]
51. Effects of nafamostat mesilate on ADP-induced platelet aggregation and disaggregation in hemodialysis patients.
Miyata M; Shirakawa T; Acharya B; Terao S; Gotoh A
ASAIO J; 2006; 52(3):272-5. PubMed ID: 16760715
[TBL] [Abstract][Full Text] [Related]
52. Real-time measurement of free thrombin: evaluation of the usability of a new thrombin assay for coagulation monitoring during extracorporeal circulation.
Krajewski S; Krauss S; Kurz J; Neumann B; Schlensak C; Wendel HP
Thromb Res; 2014 Mar; 133(3):455-63. PubMed ID: 24359968
[TBL] [Abstract][Full Text] [Related]
53. Anticoagulation intensity sufficient for haemodialysis does not prevent activation of coagulation and platelets.
Sagedal S; Hartmann A; Sundstrøm K; Bjørnsen S; Brosstad F
Nephrol Dial Transplant; 2001 May; 16(5):987-93. PubMed ID: 11328905
[TBL] [Abstract][Full Text] [Related]
54. Experimental results using nafamostat mesilate as anticoagulant during extracorporeal lung assist for 24 hours in dogs.
Okamoto T; Chung YK; Choi H; Terasaki H; Morioka T
Artif Organs; 1993 Jan; 17(1):30-6. PubMed ID: 8422232
[TBL] [Abstract][Full Text] [Related]
55. Effects of surface-bound and intravenously administered heparin on cell-surface interactions: inflammation and coagulation.
Johnson G; Curry B; Cahalan L; Prater R; Biggerstaff J; Hussain A; Gartner M; Cahalan P
Perfusion; 2013 May; 28(3):263-71. PubMed ID: 23401339
[TBL] [Abstract][Full Text] [Related]
56. Extracorporeal anticoagulation using a serine protease inhibitor in hemodialysis in sheep.
Mottaghy K; Oedekoven B; Bey R; Schmid-Schönbein H
Trans Am Soc Artif Intern Organs; 1985; 31():534-6. PubMed ID: 3939276
[No Abstract] [Full Text] [Related]
57. Plasma collection using nafamostat mesilate and dipyridamole as an anticoagulant.
Hiraishi M; Yamazaki Z; Ichikawa K; Kanai F; Idezuki Y; Onishi K; Takahama T; Inoue N
Int J Artif Organs; 1988 May; 11(3):212-6. PubMed ID: 3403059
[TBL] [Abstract][Full Text] [Related]
58. Efficacy of nafamostat mesilate as a regional anticoagulant in experimental direct hemoperfusion and in plasma exchange on humans.
Abe H; Tani T; Numa K; Endo Y; Yoshioka T; Kodama M
Artif Organs; 1992 Apr; 16(2):206-8. PubMed ID: 10078246
[TBL] [Abstract][Full Text] [Related]
59. [Effect of nafamostat mesilate on serum activities of pancreatic enzymes and plasma hormone levels].
Wakayama S; Suzuki T; Sakai T; Matsuki A
Masui; 1990 Jun; 39(6):734-40. PubMed ID: 2388392
[TBL] [Abstract][Full Text] [Related]
60. [Inhibitory effects of sepimostat mesilate (FUT-187) on the activities of trypsin-like serine proteases in vitro].
Nakamura K; Johmura A; Oda M; Ino Y; Uchiyama H; Ohtani H; Miyazaki H; Kurumi M; Akizawa Y; Oka T
Yakugaku Zasshi; 1995 Mar; 115(3):201-12. PubMed ID: 7738778
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
